Guides

What the published Phase 2 trials report about retatrutide’s side effects, the glucagon difference, and its investigational status.

AOD-9604 side effects and safety: what its human trials actually reported, why the drug failed its main efficacy test, and where the real risk lies.

What the HPLC purity % on a peptide COA really measures — area normalization, and why purity is not content, identity, or sterility.

How semaglutide and tirzepatide really differ — one incretin receptor versus two, and what the head-to-head trials show.

What a GPCR is and why it matters for peptides: the seven-transmembrane relay, the G-protein cycle, the four G-alpha families, and which peptide receptors are (and are not) GPCRs.

How research peptides are actually made: the solid-phase synthesis cycle, Boc vs Fmoc, TFA salts, and why the crude product needs HPLC and a COA.

Peptides vs small molecules: how they differ in size, specificity, oral bioavailability, half-life, immunogenicity and manufacturing — and why peptides come in vials.

Tesamorelin side effects, from the FDA-approved Egrifta label: injection-site reactions, joint pain, IGF-1 and glucose changes, antibodies, and contraindications.

Constitutive activity is agonist-independent receptor signaling. Here is what it means, why the ghrelin receptor is ~50% “on” with no ligand, and why it matters.

What is actually known about the side effects of immune peptides LL-37, KPV, and thymalin — and why product quality is the risk you can verify.